image showing a target circle

Our purpose

We protect lives from invisible threats by providing actionable health information in the right place, at the right time.

image showing a light bulb with s circle of arrows around it

Our vision

Global leaders in the fight against infectious diseases

What we do

Novacyt is a diagnostics solution provider, manufacturing diagnostic and pathogen testing kits based on molecular and protein technologies sold into human clinical, life science, food and industrial markets.

Novacyt’s Key Strengths

Customer Testimonials

cambridge image

As soon as we started to see that there was a need for COVID-19 testing, we thought of Novacyt immediately. We wanted to collaborate as soon as we can as we have a long working relationship.

Novacyt were very good; they had one of the first recognised products on the market which is the genesig® COVID-19 1G. First validation with the assay was good, and we didn’t see any problem. It is a nice assay that you can run a variety of different ways and it works on open platforms.”

Tony Cooke, CEO @ Cambridge Clinical Labs

Our Strategy

Strategic pillars

Objectives

Build the base

Build a sustainable base business across in vitro diagnostics in human health, life sciences research portfolio serving veterinary, food, water and human health with integrated instrumentation to enable semi-automated, scalable, near patient testing

  • Maximise COVID portfolio internationally “NOW”

  • Develop innovative future “non-COVID menu” for underserved market segments

  • Prioritise key markets & define go-to market strategies

  • Develop integrated instrument strategy

  • Leverage life sciences legacy business

  • Build e-commerce capability

  • The innovation engine enabling “global first response”


Global first responder

Our base business with breadth and depth of portfolio acts as the innovation engine to enable Novacyt to respond rapidly to disease outbreaks and to also serve neglected diseases. With enhanced surveillance mechanism and our agility, Novacyt continues to be a global first responder

  • Global surveillance capability

  • Latent resource capacity

  • Install “COBRA-like” internal response team

  • Address customer complexity

  • Agile resource deployment

  • Appoint global scientific expert panel

PDF Download

Financial highlights

Operational highlights

  • Rapid development and launch of 15 new assays to support laboratories, clinicians, and private testing of COVID-19 since the beginning of 2021

  • Launch of VersaLab™ mobile processing laboratories and VersaLab™ Portable to expand near-patient testing opportunities in private sector testing

  • Inclusion in National Framework Agreement, resulting in a new £4.7m contract with the DHSC for the supply of PROmate® COVID-19 tests to the NHS

  • Secured new contracts with WHO and UNICEF for the supply of COVID-19 products

  • Growth of new markets for private testing, including travel, sport, film, media, and workplace settings

PDF Download

Financial highlights

Operational highlights

  • Rapid development and launch of 15 new assays to support laboratories, clinicians, and private testing of COVID-19 since the beginning of 2021

  • Launch of VersaLab™ mobile processing laboratories and VersaLab™ Portable to expand near-patient testing opportunities in private sector testing

  • Inclusion in National Framework Agreement, resulting in a new £4.7m contract with the DHSC for the supply of PROmate® COVID-19 tests to the NHS

  • Secured new contracts with WHO and UNICEF for the supply of COVID-19 products

  • Growth of new markets for private testing, including travel, sport, film, media, and workplace settings

PDF Download